Patents by Inventor Takahiko HASHIZUKA

Takahiko HASHIZUKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer
    Publication number: 20230250116
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Application
    Filed: November 10, 2022
    Publication date: August 10, 2023
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
    Patent number: 11530231
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: December 20, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • SALTS OF A HETEROCYCLIC COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20220098163
    Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
    Type: Application
    Filed: June 15, 2021
    Publication date: March 31, 2022
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Nandkumar Nivritti BHOGLE, Takahiko HASHIZUKA, Robert Joseph PRYTKO, John R. SNOONIAN, Harold Scott WILKINSON, Haitao ZHANG
  • CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer
    Publication number: 20210332071
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Application
    Filed: April 8, 2021
    Publication date: October 28, 2021
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
    Patent number: 11136304
    Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 5, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
  • Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
    Patent number: 11066380
    Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: July 20, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Nandkumar Nivritti Bhogle, Takahiko Hashizuka, Robert Joseph Prytko, John R. Snoonian, Harold Scott Wilkinson, Haitao Zhang
  • CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
    Patent number: 11034710
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: June 15, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • SALTS OF A HETEROCYCLIC COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20200290987
    Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 17, 2020
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Nandkumar Nivritti BHOGLE, Takahiko HASHIZUKA, Robert Joseph PRYTKO, John R. SNOONIAN, Harold Scott WILKINSON, Haitao ZHANG
  • CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER
    Publication number: 20200255462
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Application
    Filed: December 4, 2019
    Publication date: August 13, 2020
    Inventors: Adam SIDDIQUI-JAIN, Paul FLYNN, Yuji FUJIWARA, Shuji MASUMOTO, Hiroaki TANAKA, Hirotaka KUREBAYASHI, Takahiko HASHIZUKA, Yuka ARIKAWA